Dolby Family Ventures Research
Investment Thesis
Dolby Family Ventures (DFV) is a San Francisco-based early-stage venture firm founded in 2014 by David Dolby, formalizing the Dolby family's multi-generational commitment, rooted in Ray Dolby's engineering legacy, to funding visionary entrepreneurs solving intractable science and engineering problems. The firm explicitly frames its mission around a "double bottom line": realizing both positive societal impact and financial return. DFV backs founders willing to work through long, uncertain research horizons rather than chasing near-term, low-risk opportunities.
Sector Focus
DFV invests across five core areas: precision neuroscience, life sciences platforms, aerospace, climate tech, and digital deep tech.
- Precision neuroscience: disease-modifying therapeutics, devices, and diagnostics spanning neurodegeneration, psychiatry, and neurotech/brain-computer interfaces, with an especially deep and long-running focus on Alzheimer's disease and depression.
- Life sciences platforms: de novo drug discovery platforms, computational biology, regenerative medicine, and provider-operations technology.
- Aerospace: satellite propulsion, orbital services, space situational awareness, and next-generation aircraft/maritime propulsion.
- Climate tech: carbon transformation, advanced nuclear fuel supply chains, battery materials, and industrial/grid monitoring.
- Digital deep tech: cybersecurity, AR/VR optics, spatial computing, robotics, and AI/ML infrastructure.
DFV explicitly does not invest in non-platform companies in oncology, cardiovascular disease, or rare diseases within life sciences.
Stage Focus
DFV prioritizes preseed, seed, and Series A rounds for a company's first DFV investment, and will occasionally invest at later stages case-by-case. It also frequently makes follow-on investments across a portfolio company's lifecycle; several relationships (e.g., Ursa Major Technologies, Cerevance, Cytovale) have spanned from Series A through Series D.
Check Size
Third-party sources place typical initial checks in the $2M-$7M range, with the firm's original 2014 launch materials citing roughly $3M in capital at risk per company and 4-7 new investments per year. Exact figures are not published on the firm's own site.
Lead Tendency
DFV describes itself as investing "only in conjunction with strong investment syndicate partners," and typically holds a fiduciary or observer board position initially rather than insisting on a lead/control position. Founder testimonials (e.g., from Twelve's CEO) credit DFV with "bringing in co-investors" early in a company's life, suggesting DFV often plays an active syndicate-building role without always being the headline lead.
Recent Activity
DFV remains actively engaged across its portfolio as of late 2026. Recent portfolio milestones and financings include REGENT's $240M Series B (Aug 2026) to scale Seaglider maritime vessel manufacturing, Paradromics receiving FDA approval to embed BCI software in personal devices (Aug 2026) after also gaining approval to trial its brain implant in humans (Nov 2025) and completing its first human implant (Jun 2026), Ursa Major Technologies' planned SPAC public listing (Aug 2026), Molten Salt Solutions' $7M raise to scale lithium enrichment for advanced nuclear energy (Aug 2026), and continued clinical progress at Montara Therapeutics, Motif Neurotech, QurAlis, and Vandria.
Portfolio Highlights
Over more than a decade, DFV has backed roughly 100 companies, with a strong track record of exits:
- IPOs: Athira Pharma (ATHA), Yumanity Therapeutics (YMTX), Cognition Therapeutics (CGTX), Cortexyme (CRTX), Hyperfine Research (HYPR), Eargo (EAR), Cogstate (CGS), Tempo Automation (TMPO)
- Notable acquisitions: Niantic Labs (Pokémon Go, acquired by Scopely), August (Assa Abloy), Wickr (Amazon), Herophilus (Genentech), Tetra Therapeutics (Shionogi), Lightform (Amazon), UltraLeap (ROLI), Motiv Ring (Proxy)
- Currently active flagship names: Paradromics, Cerevance, Cajal Neuroscience, Cytovale, Twelve, Ursa Major Technologies, DigiLens, Mojo Vision, Cala Health, Bionaut Labs, Salvia BioElectronics, and NextSense
Team
DFV's core team blends investing, scientific, and operating experience:
- David Dolby, CEO
- Pascal Levensohn, Executive Chairman
- Andrew Krowne, Managing Partner
- Reetika Bhardwaj, PhD, Principal
- Lin Ning, PhD, Senior Associate
- Usua Amanam, PhD, Senior Associate
- Mei Liang, Vice President, Finance
- Alona Cochran, Office Manager & Executive Assistant
- Michál de Beer, Analyst
DFV also maintains a Scientific Advisory Board of leading Alzheimer's, psychiatry, and neurotechnology experts, including Michael Weiner (UCSF/ADNI), Rudolph Tanzi, Lennart Mucke (Gladstone Institute/UCSF), Husseini Manji, Howard Fillit, Maurizio Fava, and Edward Chang, who evaluate early-stage disease-modifying-therapeutic opportunities.
Decision Process
Investment decisions appear to run through the partner team (Dolby, Levensohn, Krowne, and investment staff) with formal scientific diligence support from the Scientific Advisory Board for neuroscience/Alzheimer's opportunities. The firm notes it reviews "several hundred opportunities every year" but invests selectively.
Founder Preferences
DFV's own homepage frames its ideal partners as "independent thinkers, helpful, high moral character," explicitly prioritizing character alongside technical excellence. It seeks technical founders (scientists and engineers) willing to sit with long uncertainty horizons, and explicitly funds a "poly-solution" portfolio of parallel approaches to the same hard problem (e.g., many independent bets on Alzheimer's disease) rather than a single best guess.
Geographic Focus
DFV is headquartered in San Francisco, CA (999 Brannan Street). Its portfolio is overwhelmingly US-based, spanning the Bay Area, the Boston/Cambridge biotech cluster, and other US innovation hubs, with no evidence of an explicit international mandate.